Risk period for developing osteonecrosis of the femoral head in patients on steroid treatment

K. H. Koo, R. Kim, Y. S. Kim, I. O. Ahn, S. H. Cho, Hae Ryong Song, Y. S. Park, H. Kim, G. J. Wang

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

Patients who require long-term steroid use are at risk for the development of osteonecrosis. However, the risk period for developing osteonecrosis of the femoral head has not yet been defined. The authors attempted to determine the onset of osteonecrosis of the femoral head following steroid treatment. Medical record data of patients with steroid-related osteonecrosis of the femoral head from four university hospitals were reviewed. Information was collected regarding the duration and dose of steroid use for patients who were diagnosed at the early stage by magnetic resonance imaging (MRI) without positive findings on plain radiographs (Association Research Circulation Osseous stage I osteonecrosis). Twenty-two patients were diagnosed at Association Research Circulation Osseous stage I. There were eight male and 14 female patients ranging in age from 17 to 60 years (mean 33). The total dose of steroid, which was used until the time of detection of osteonecrosis by MRI, ranged from 1800 to 15 505 mg prednisolone or its equivalent (mean 5928 mg). The period from the start of steroid treatment to the diagnosis by MRI ranged from I month to 16 months (mean 5.3 months). Twenty-one of 22 patients were diagnosed within 12 months of the initiation of steroid treatment. The duration of steroid treatment within this period ranged from I month to 12 months (mean 4.5 months). There may be a risk period of 12 months for developing femoral head osteonecrosis in patients receiving long-term steroid treatment. Close observation and more aggressive screening are recommended within the first year of long-term steroid treatment to prevent advanced osteonecrosis of the femoral head.

Original languageEnglish
Pages (from-to)299-303
Number of pages5
JournalClinical Rheumatology
Volume21
Issue number4
DOIs
Publication statusPublished - 2002 Aug 1
Externally publishedYes

Fingerprint

Osteonecrosis
Thigh
Steroids
Therapeutics
Magnetic Resonance Imaging
Prednisolone
Research
Medical Records
Observation

Keywords

  • Femoral head
  • Osteonecrosis
  • Steroid

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Risk period for developing osteonecrosis of the femoral head in patients on steroid treatment. / Koo, K. H.; Kim, R.; Kim, Y. S.; Ahn, I. O.; Cho, S. H.; Song, Hae Ryong; Park, Y. S.; Kim, H.; Wang, G. J.

In: Clinical Rheumatology, Vol. 21, No. 4, 01.08.2002, p. 299-303.

Research output: Contribution to journalArticle

Koo, KH, Kim, R, Kim, YS, Ahn, IO, Cho, SH, Song, HR, Park, YS, Kim, H & Wang, GJ 2002, 'Risk period for developing osteonecrosis of the femoral head in patients on steroid treatment', Clinical Rheumatology, vol. 21, no. 4, pp. 299-303. https://doi.org/10.1007/s100670200078
Koo, K. H. ; Kim, R. ; Kim, Y. S. ; Ahn, I. O. ; Cho, S. H. ; Song, Hae Ryong ; Park, Y. S. ; Kim, H. ; Wang, G. J. / Risk period for developing osteonecrosis of the femoral head in patients on steroid treatment. In: Clinical Rheumatology. 2002 ; Vol. 21, No. 4. pp. 299-303.
@article{6af41fc8470a404b8f99ca18471539cf,
title = "Risk period for developing osteonecrosis of the femoral head in patients on steroid treatment",
abstract = "Patients who require long-term steroid use are at risk for the development of osteonecrosis. However, the risk period for developing osteonecrosis of the femoral head has not yet been defined. The authors attempted to determine the onset of osteonecrosis of the femoral head following steroid treatment. Medical record data of patients with steroid-related osteonecrosis of the femoral head from four university hospitals were reviewed. Information was collected regarding the duration and dose of steroid use for patients who were diagnosed at the early stage by magnetic resonance imaging (MRI) without positive findings on plain radiographs (Association Research Circulation Osseous stage I osteonecrosis). Twenty-two patients were diagnosed at Association Research Circulation Osseous stage I. There were eight male and 14 female patients ranging in age from 17 to 60 years (mean 33). The total dose of steroid, which was used until the time of detection of osteonecrosis by MRI, ranged from 1800 to 15 505 mg prednisolone or its equivalent (mean 5928 mg). The period from the start of steroid treatment to the diagnosis by MRI ranged from I month to 16 months (mean 5.3 months). Twenty-one of 22 patients were diagnosed within 12 months of the initiation of steroid treatment. The duration of steroid treatment within this period ranged from I month to 12 months (mean 4.5 months). There may be a risk period of 12 months for developing femoral head osteonecrosis in patients receiving long-term steroid treatment. Close observation and more aggressive screening are recommended within the first year of long-term steroid treatment to prevent advanced osteonecrosis of the femoral head.",
keywords = "Femoral head, Osteonecrosis, Steroid",
author = "Koo, {K. H.} and R. Kim and Kim, {Y. S.} and Ahn, {I. O.} and Cho, {S. H.} and Song, {Hae Ryong} and Park, {Y. S.} and H. Kim and Wang, {G. J.}",
year = "2002",
month = "8",
day = "1",
doi = "10.1007/s100670200078",
language = "English",
volume = "21",
pages = "299--303",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "4",

}

TY - JOUR

T1 - Risk period for developing osteonecrosis of the femoral head in patients on steroid treatment

AU - Koo, K. H.

AU - Kim, R.

AU - Kim, Y. S.

AU - Ahn, I. O.

AU - Cho, S. H.

AU - Song, Hae Ryong

AU - Park, Y. S.

AU - Kim, H.

AU - Wang, G. J.

PY - 2002/8/1

Y1 - 2002/8/1

N2 - Patients who require long-term steroid use are at risk for the development of osteonecrosis. However, the risk period for developing osteonecrosis of the femoral head has not yet been defined. The authors attempted to determine the onset of osteonecrosis of the femoral head following steroid treatment. Medical record data of patients with steroid-related osteonecrosis of the femoral head from four university hospitals were reviewed. Information was collected regarding the duration and dose of steroid use for patients who were diagnosed at the early stage by magnetic resonance imaging (MRI) without positive findings on plain radiographs (Association Research Circulation Osseous stage I osteonecrosis). Twenty-two patients were diagnosed at Association Research Circulation Osseous stage I. There were eight male and 14 female patients ranging in age from 17 to 60 years (mean 33). The total dose of steroid, which was used until the time of detection of osteonecrosis by MRI, ranged from 1800 to 15 505 mg prednisolone or its equivalent (mean 5928 mg). The period from the start of steroid treatment to the diagnosis by MRI ranged from I month to 16 months (mean 5.3 months). Twenty-one of 22 patients were diagnosed within 12 months of the initiation of steroid treatment. The duration of steroid treatment within this period ranged from I month to 12 months (mean 4.5 months). There may be a risk period of 12 months for developing femoral head osteonecrosis in patients receiving long-term steroid treatment. Close observation and more aggressive screening are recommended within the first year of long-term steroid treatment to prevent advanced osteonecrosis of the femoral head.

AB - Patients who require long-term steroid use are at risk for the development of osteonecrosis. However, the risk period for developing osteonecrosis of the femoral head has not yet been defined. The authors attempted to determine the onset of osteonecrosis of the femoral head following steroid treatment. Medical record data of patients with steroid-related osteonecrosis of the femoral head from four university hospitals were reviewed. Information was collected regarding the duration and dose of steroid use for patients who were diagnosed at the early stage by magnetic resonance imaging (MRI) without positive findings on plain radiographs (Association Research Circulation Osseous stage I osteonecrosis). Twenty-two patients were diagnosed at Association Research Circulation Osseous stage I. There were eight male and 14 female patients ranging in age from 17 to 60 years (mean 33). The total dose of steroid, which was used until the time of detection of osteonecrosis by MRI, ranged from 1800 to 15 505 mg prednisolone or its equivalent (mean 5928 mg). The period from the start of steroid treatment to the diagnosis by MRI ranged from I month to 16 months (mean 5.3 months). Twenty-one of 22 patients were diagnosed within 12 months of the initiation of steroid treatment. The duration of steroid treatment within this period ranged from I month to 12 months (mean 4.5 months). There may be a risk period of 12 months for developing femoral head osteonecrosis in patients receiving long-term steroid treatment. Close observation and more aggressive screening are recommended within the first year of long-term steroid treatment to prevent advanced osteonecrosis of the femoral head.

KW - Femoral head

KW - Osteonecrosis

KW - Steroid

UR - http://www.scopus.com/inward/record.url?scp=0036692970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036692970&partnerID=8YFLogxK

U2 - 10.1007/s100670200078

DO - 10.1007/s100670200078

M3 - Article

C2 - 12189457

AN - SCOPUS:0036692970

VL - 21

SP - 299

EP - 303

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 4

ER -